We investigated the potential value of prostate-specific antigen half-life （PSAHL） and decreasing velocity （PSAVd） to predict progression-free survival （PFS） and overall survival （OS） in Chinese patients with ...We investigated the potential value of prostate-specific antigen half-life （PSAHL） and decreasing velocity （PSAVd） to predict progression-free survival （PFS） and overall survival （OS） in Chinese patients with prostate cancer. A total of 153 patients treated with hormonal therapy were included in the study. Of these, 78 patients progressed to hormone- refractory prostate cancer （HRPC） and 24 patients died by the end of follow-up. PSAHL was defined as the time during which prostate-specific antigen （PSA） concentration became half of the initial value during the first hormonal therapy. PSAVd reflected the decreasing velocity of PSA during the first hormonal therapy. PFS was defined as the interval from the beginning of hormonal therapy to HRPC. Cox proportional hazards regression analysis was used to evaluate whether PSAHL and PSAVd were significantly associated with PFS and OS. The median PSAHL and PSAVd were 0.50 months and 33.8 ng mL^-1 per month. The median PFS and OS were 22.7 months （95% confidence interval [CI], 22.0-29.6 months） and 43.5 months （95% CI, 37.9-48.4 months）, respectively. On univariate and multivariate analysis, long PSAHL （〉 0.5 months）, metastatic disease, high biopsy Gleason scores （〉 8） and high nadir PSA （〉 0.4 ng mL^-1） were all found to be significantly associated with short PFS. Long PSAHL, high nadir PSA and short PSA doubling time （PSADT 〈 2.0 months） were significantly associated with short OS. There were no significant relationships between PSAVd and either PFS or OS. Thus, PSAHL is a promising new independent predictor of survival. Patients with long PSAHL were identified as those at high risk for a relatively short PFS and OS.展开更多
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antige...We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.展开更多
目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳...目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳入27例接受NHT的PCa患者的临床资料,根据术后病理学检查结果分为有效组(n=16)和无效组(n=11)。对比两组患者临床病理学特征、治疗前后血清前列腺特异性抗原(prostate-specific antigen,PSA)和CETRUS检查指标及其变化率,以筛选与NHT反应性有关的潜在指标。进一步采用相关性分析评价其在评估患者对NHT反应方面的价值。结果:有效组和无效组在临床病理学特征、治疗前的血清PSA和C E T R U S检查指标方面的差异无统计学意义(均P>0.05)。治疗后,仅有效组的TIC曲线下面积(area under curve,AUC)低于无效组(560 dB·s vs 710 dB·s),其变化率大于无效组(-27.1%vs-5.3%)(均P<0.05)。相关性分析显示AUC变化率与组织学反应评分之间的相关性略高于治疗后AUC(r为-0.690 vs-0.630)。结论:CETRUS TIC参数中,NHT后的AUC及其变化率在评估PCa患者对NHT反应方面具有较好的价值。其中,AUC变化率可能与治疗反应程度更相关。展开更多
Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these pati...Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen （PSA） level 〉50% during the treatment and investigated the potential role of time to nadir （TTN） of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival （OS）. In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN 〈17 weeks （42.83 vs 21.50 weeks, P 〈 0.001）. The time to PSA progression in patients with TTN ：〉17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was 〈17 weeks. We found several factors to be associated with OS, including TTN （hazard ratio [HR]. 3.937, 95% confidence interval [CI]： 1.502-10.309, P = 0.005）, PSA level at the diagnosis of cancer （HR： 4,337, 95% CI： 1.616-11.645, P= 0.004）, duration of initial androgen deprivation therapy （HR： 2.982, 95% CI： 1.104-8.045, P= 0.031）, neutrophil-to-lymphocyte ratio （HR： 3.963, 95% CI： 1.380-11.384, P = 0.011）, and total PSA response （Class 1 [〈0 response] compared to Class 2 [0-50% response], HR： 3.978, 95% CI： 1.278-12.387, P = 0.017）. In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have 〉50% PSA remission.展开更多
目的探讨外周血前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达在前列腺癌早期诊断中的应用。方法选取2015年10月至2016年12月因前列腺疾病于本院初次就诊的患者以及健康体检者共120例男性为研究对象。其中确诊前列腺癌46例(...目的探讨外周血前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达在前列腺癌早期诊断中的应用。方法选取2015年10月至2016年12月因前列腺疾病于本院初次就诊的患者以及健康体检者共120例男性为研究对象。其中确诊前列腺癌46例(局限性前列腺癌27例、非局限性前列腺癌19例),前列腺增生40例,前列腺炎24例,健康体检者10例。采用实时荧光定量PCR技术(Taqman探针)检测研究对象外周血中PCA3 mRNA的模板数,比较其在不同组别中的表达含量,探讨其与前列腺癌诊断的相关性。结果 PCA3基因仅在前列腺癌组(31/46)和前列腺增生组(4/40)中表达,在其余组中均未见表达;非局限性前列腺癌组患者外周血PCA3基因表达量显著高于局限性前列腺癌组(P<0.001)。结论 PCA3基因是前列腺癌的特异性肿瘤标志物,外周血PCA3基因检测有助于前列腺癌的早期诊断。展开更多
目的前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达具有前列腺癌特异性,文中建立荧光实时定量PCR(FQ-RT-PCR)检测PCA3评分的方法。方法分别以LNCap和PC-3细胞株为阳性和阴性对照,用TaqMan探针建立检测PCA3和前列腺特异性抗原(...目的前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达具有前列腺癌特异性,文中建立荧光实时定量PCR(FQ-RT-PCR)检测PCA3评分的方法。方法分别以LNCap和PC-3细胞株为阳性和阴性对照,用TaqMan探针建立检测PCA3和前列腺特异性抗原(prostate specific antigen,PSA)mRNA的荧光实时定量PCR方法,评价特异性、重复性和计算扩增效率,建立PCA3评分计算公式。结果检测PCA3和PSA mRNA的批内变异系数分别为1.19%、1.09%、0.84%和0.06%、0.71%、0.79%,批间变异系数分别为1.03%和0.56%;扩增效率分别为0.98和1.00;以2-ΔCt表示PCA3评分。结论荧光实时定量PCR检测PCA3评分方法的特异性好,重复性高。展开更多
文摘We investigated the potential value of prostate-specific antigen half-life （PSAHL） and decreasing velocity （PSAVd） to predict progression-free survival （PFS） and overall survival （OS） in Chinese patients with prostate cancer. A total of 153 patients treated with hormonal therapy were included in the study. Of these, 78 patients progressed to hormone- refractory prostate cancer （HRPC） and 24 patients died by the end of follow-up. PSAHL was defined as the time during which prostate-specific antigen （PSA） concentration became half of the initial value during the first hormonal therapy. PSAVd reflected the decreasing velocity of PSA during the first hormonal therapy. PFS was defined as the interval from the beginning of hormonal therapy to HRPC. Cox proportional hazards regression analysis was used to evaluate whether PSAHL and PSAVd were significantly associated with PFS and OS. The median PSAHL and PSAVd were 0.50 months and 33.8 ng mL^-1 per month. The median PFS and OS were 22.7 months （95% confidence interval [CI], 22.0-29.6 months） and 43.5 months （95% CI, 37.9-48.4 months）, respectively. On univariate and multivariate analysis, long PSAHL （〉 0.5 months）, metastatic disease, high biopsy Gleason scores （〉 8） and high nadir PSA （〉 0.4 ng mL^-1） were all found to be significantly associated with short PFS. Long PSAHL, high nadir PSA and short PSA doubling time （PSADT 〈 2.0 months） were significantly associated with short OS. There were no significant relationships between PSAVd and either PFS or OS. Thus, PSAHL is a promising new independent predictor of survival. Patients with long PSAHL were identified as those at high risk for a relatively short PFS and OS.
文摘We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
文摘目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳入27例接受NHT的PCa患者的临床资料,根据术后病理学检查结果分为有效组(n=16)和无效组(n=11)。对比两组患者临床病理学特征、治疗前后血清前列腺特异性抗原(prostate-specific antigen,PSA)和CETRUS检查指标及其变化率,以筛选与NHT反应性有关的潜在指标。进一步采用相关性分析评价其在评估患者对NHT反应方面的价值。结果:有效组和无效组在临床病理学特征、治疗前的血清PSA和C E T R U S检查指标方面的差异无统计学意义(均P>0.05)。治疗后,仅有效组的TIC曲线下面积(area under curve,AUC)低于无效组(560 dB·s vs 710 dB·s),其变化率大于无效组(-27.1%vs-5.3%)(均P<0.05)。相关性分析显示AUC变化率与组织学反应评分之间的相关性略高于治疗后AUC(r为-0.690 vs-0.630)。结论:CETRUS TIC参数中,NHT后的AUC及其变化率在评估PCa患者对NHT反应方面具有较好的价值。其中,AUC变化率可能与治疗反应程度更相关。
基金This study was partially supported by the National Natural Science Foundation of China （NSFC 81202014 to KJW, NSFC 81130041 to DLH） and the Fundamental Research Funds for the Central Universities （to KIW）.
文摘Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen （PSA） level 〉50% during the treatment and investigated the potential role of time to nadir （TTN） of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival （OS）. In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN 〈17 weeks （42.83 vs 21.50 weeks, P 〈 0.001）. The time to PSA progression in patients with TTN ：〉17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was 〈17 weeks. We found several factors to be associated with OS, including TTN （hazard ratio [HR]. 3.937, 95% confidence interval [CI]： 1.502-10.309, P = 0.005）, PSA level at the diagnosis of cancer （HR： 4,337, 95% CI： 1.616-11.645, P= 0.004）, duration of initial androgen deprivation therapy （HR： 2.982, 95% CI： 1.104-8.045, P= 0.031）, neutrophil-to-lymphocyte ratio （HR： 3.963, 95% CI： 1.380-11.384, P = 0.011）, and total PSA response （Class 1 [〈0 response] compared to Class 2 [0-50% response], HR： 3.978, 95% CI： 1.278-12.387, P = 0.017）. In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have 〉50% PSA remission.
文摘目的前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达具有前列腺癌特异性,文中建立荧光实时定量PCR(FQ-RT-PCR)检测PCA3评分的方法。方法分别以LNCap和PC-3细胞株为阳性和阴性对照,用TaqMan探针建立检测PCA3和前列腺特异性抗原(prostate specific antigen,PSA)mRNA的荧光实时定量PCR方法,评价特异性、重复性和计算扩增效率,建立PCA3评分计算公式。结果检测PCA3和PSA mRNA的批内变异系数分别为1.19%、1.09%、0.84%和0.06%、0.71%、0.79%,批间变异系数分别为1.03%和0.56%;扩增效率分别为0.98和1.00;以2-ΔCt表示PCA3评分。结论荧光实时定量PCR检测PCA3评分方法的特异性好,重复性高。
